N-LIfT PLATFORM PIPELINE

Our strategy is to initially target high unmet need solid tumours that qualify as rare (orphan) diseases where successful therapies can qualify for both Accelerated Regulatory Approval and Market Exclusivity Status. We are targeting the following solid tumour types (or subsets of):

pipeline.png